1UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland. 2Systems Biology Ireland, UCD School of Medicine, University College Dublin, ...
A committee of three scientists named by the CEBP Editor-in-Chief selects the Award winner each year based on the committee’s evaluation of the following criteria: originality; scientific, clinical, ...
Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...
1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts. 2Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts. 3Ludwig MIT Center for Molecular ...
1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. *Corresponding Author: Cari M. Kitahara, Division of ...
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.
1Baylor College of Medicine, Houston, TX.
1Adult Stem Cell Research Center and Research Institute for Veterinary Science, Seoul, Republic of Korea.
Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.
B cell–depleting therapies impair antibody responses in 2-dose series of mRNA vaccination against SARS-CoV-2, urging research on additional protection against COVID-19 in patients with B-cell ...
Cancer Res (2025) 85 (8_Supplement_1): 6376.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback